Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISION trial of anakinra for inflammatory respiratory post-acute COVID syndrome
2023-000102-25Phase 2Active
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Feb 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID syndrome comparing Anakinra for 8 weeks with Anakinra for 4 weeks then placebo for 4 weeks (2 arms). Primary endpoint: Score of PACS progression reversal. Started Feb 2023; status: active.
02
Drugs
anakinra
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2023-000102-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000102-25.